@article{oai:tohoku-mpu.repo.nii.ac.jp:00000863,
 author = {池, 瑛莉奈 and Ike, Erina and 大内, 竜介 and Ouchi, Ryusuke and 薄井, 健介 and Usui, Kensuke and 鈴木, 清寿 and Suzuki, Shinju and 長尾, 宗紀 and Nagao, Munenori and 児山, 香 and Koyama, Kaori and 高橋, 知子 and Takahashi, Tomoko and 岡田, 浩司 and Okada, Kouji},
 issue = {68},
 journal = {東北医科薬科大学研究誌, Journal of Tohoku Medical and Pharmaceutical University},
 month = {Dec},
 note = {Lapatinib ditosylate monohydrate, an oral tyrosine kinase inhibitor selective for epidermal growth factor receptor and human epidermal growth factor receptor type 2, can be used to treat inoperable or metastatic recurrent breast cancer with confirmed HER2 overexpression. However, its discontinuation from treatment due to diarrhea, a frequently occurring side effect, has become a problem. Therefore, defecation control is important. A guide for the appropriate use of tykerb®tablets recommends the use of loperamide hydrochloride according to the severity of the diarrhea. We report a complex case of defecation control where a patient had constipation by prior opioid analgesics before taking lapatinib ditosylate monohydrate, which resulted in diarrhea. Lapatinib ditosylate monohydrate was continued without reduction or discontinuation as we adjusted the drugs involved in defecation control additionally, the pre-administered opioid analgesics were continued while unifying the evaluation criteria for defecation and monitoring the patient continuously. Therefore, when introducing an anticancer drug with a high risk of diarrhea to patients who have previously taken opioid analgesics, it is important to evaluate defecation based on a unified evaluation standard. If opioid analgesics have been used in advance, it is important to control defecation considering the antidiarrheal effect of opioid analgesics.},
 pages = {9--16},
 title = {【症例報告】先行オピオイドを考慮しラパチニブ誘発性下痢をコントロールした一例},
 year = {2021},
 yomi = {イケ, エリナ and オオウチ, リュウスケ and ウスイ, ケンスケ and スズキ, シンジュ and ナガオ, ムネノリ and コヤマ, カオリ and タカハシ, トモコ and オカダ, コウジ}
}